The Microculture-Kinetic (MiCK) Assay: The Role of a Drug-Induced Apoptosis Assay in Drug Development and Clinical Care

被引：13

作者：

Bosserman, Linda ^{[1
]}

Prendergast, Franklyn ^{[2
]}

Herbst, Roy ^{[3
]}

Fleisher, Martin ^{[4
]}

Salom, Emery ^{[5
]}

Strickland, Steven ^{[6
]}

Raptis, Anastasios ^{[10
]}

Hallquist, Allan ^{[7
]}

Perree, Mathieu ^{[7
]}

Rajurkar, Swapnil ^{[1
]}

Karimi, Misagh ^{[1
]}

Rogers, Karl ^{[8
]}

Davidson, Dirk ^{[9
]}

Willis, Carl ^{[8
]}

Penalver, Manuel ^{[5
]}

Homesley, Howard ^{[12
]}

Burrell, Matthew ^{[13
]}

Garrett, Audrey ^{[14
]}

Rutledge, James ^{[15
]}

Chernick, Michael ^{[11
]}

Presant, Cary A. ^{[1
,7
]}

机构：

[1] Wilshire Oncol Med Grp US Oncol, La Verne, CA 91750 USA

[2] Mayo Clin, Rochester, MN USA

[3] Yale Canc Ctr, New Haven, CT USA

[4] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA

[5] S Florida Gynecol Oncol, Coral Gables, FL USA

[6] Vanderbilt Canc Ctr, Nashville, TN USA

[7] DiaTech Oncol, Nashville, TN USA

[8] NashvilleOncol Associates, Nashville, TN USA

[9] Tennessee Plateau Oncol, Crossville, TN USA

[10] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA

[11] Lankenau Inst Med, Wynnewood, PA USA

[12] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[13] Northside Hosp Atlanta, Atlanta, GA USA

[14] Sacred Heart Med Ctr, Eugene, OR USA

[15] Data Vis, Dayton, OH USA

来源：

CANCER RESEARCH | 2012年 / 72卷 / 16期

关键词：

IN-VITRO; CHEMOTHERAPY SENSITIVITY; SURVIVAL;

D O I：

10.1158/0008-5472.CAN-12-0681

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

A drug-induced apoptosis assay, termed the microculture-kinetic (MiCK) assay, has been developed. Blinded clinical trials have shown higher response rates and longer survival in groups of patients with acute myelocytic leukemia and epithelial ovarian cancer who have been treated with drugs that show high apoptosis in the MiCK assay. Unblinded clinical trials in multiple tumor types have shown that the assay will be used frequently by clinicians to determine treatment, and when used, results in higher response rates, longer times to relapse, and longer survivals. Model economic analyses suggest possible cost savings in clinical use based on increased generic drug use and single-agent substitution for combination therapies. Two initial studies with drugs in development are promising. The assay may help reduce costs and speed time to drug approval. Correlative studies with molecular biomarkers are planned. This assay may have a role both in personalized clinical therapy and in more efficient drug development. Cancer Res; 72(16); 3901-5. (C)2012 AACR.

引用

页码：3901 / 3905

页数：5

共 14 条

[11]

Salom EM, 2010, J CLIN ONCOL S, V28, p15s

[12] Chemotherapy sensitivity and resistance assays: A systematic review [J].

Samson, DJ ;

Seidenfeld, J ;

Ziegler, K ;

Aronson, N .

JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (17) :3618-3630

[13]

Schultz R, 2000, P 11 NCI EORTC AACR

[14] In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma:: A multicenter phase II trial of the dermatologic cooperative oncology group [J].

Ugurel, Selma ;

Schadenclorf, Dirk ;

Pfoehler, Claudia ;

Neuber, Karsten ;

Thoelke, Adina ;

Ulrich, Jens ;

Hauschild, Axel ;

Spieth, Konstanze ;

Kaatz, Martin ;

Rittgen, Werner ;

Delorme, Stefan ;

Tilgen, Wolfgang ;

Reinhold, Uwe .

CLINICAL CANCER RESEARCH, 2006, 12 (18) :5454-5463

← 1 2 →